Compare ADMA & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADMA | WD |
|---|---|---|
| Founded | 2004 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2012 | 2010 |
| Metric | ADMA | WD |
|---|---|---|
| Price | $10.32 | $51.55 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $25.67 | ★ $76.00 |
| AVG Volume (30 Days) | ★ 4.7M | 188.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 5.34% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.60 | ★ 1.64 |
| Revenue | $42,219,783.00 | ★ $1,234,306,000.00 |
| Revenue This Year | $27.46 | $20.60 |
| Revenue Next Year | $22.11 | $7.79 |
| P/E Ratio | ★ $17.16 | $31.15 |
| Revenue Growth | ★ 43.85 | 8.99 |
| 52 Week Low | $7.21 | $42.12 |
| 52 Week High | $23.98 | $90.00 |
| Indicator | ADMA | WD |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 59.59 |
| Support Level | $7.21 | $48.44 |
| Resistance Level | $11.42 | $52.44 |
| Average True Range (ATR) | 0.48 | 1.57 |
| MACD | 0.10 | 0.23 |
| Stochastic Oscillator | 15.69 | 70.50 |
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.